PubMed

Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia.

Deeg MA, Buse JB, Goldberg RB, Kendall DM, Zagar AJ, Jacober SJ, Khan MA, Perez AT, Tan MH; GLAI Study Investigators.

Diabetes Care. 2007 Oct;30(10):2458-64. Epub 2007 Jun 26.PMID: 17595355 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance.

Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, Pugh K, Jenkins AJ, Klein RL, Liao Y.

Diabetes. 2003 Feb;52(2):453-62.PMID: 12540621 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.

Mattoo V, Eckland D, Widel M, Duran S, Fajardo C, Strand J, Knight D, Grossman L, Oakley D, Tan M; H6E-MC-GLAT study group.

Clin Ther. 2005 May;27(5):554-67.PMID: 15978304 [PubMed - indexed for MEDLINE]Related articles

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.

Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE; Pioglitazone 026 Study Group.

Coron Artery Dis. 2001 Aug;12(5):413-23.PMID: 11491207 [PubMed - indexed for MEDLINE]Related articles

A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone.

Khan MA, St Peter JV, Xue JL.

Diabetes Care. 2002 Apr;25(4):708-11.PMID: 11919129 [PubMed - indexed for MEDLINE]Related articlesFree article

Peroxisome proliferator-activated receptor-gamma agonist increases both low-density lipoprotein cholesterol particle size and small high-density lipoprotein cholesterol in patients with type 2 diabetes independent of diabetic control.

Bavirti S, Ghanaat F, Tayek JA.

Endocr Pract. 2003 Nov-Dec;9(6):487-93.PMID: 14715475 [PubMed - indexed for MEDLINE]Related articles

Lipoprotein effects of different thiazolidinediones in clinical practice.

Ovalle F, Bell DS.

Endocr Pract. 2002 Nov-Dec;8(6):406-10.PMID: 15251829 [PubMed - indexed for MEDLINE]Related articles

Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: effects on the very-low-density and high-density lipoprotein particle distribution.

Gómez-Pérez FJ, Aguilar-Salinas CA, Vázquez-Chávez C, Fanghänel-Salmón G, Gallegos-Martínez J, Gómez-Diaz RA, Salinas-Orozco S, Chavira-López IJ, Sánchez-Reyes L, Torres-Acosta EM, Tamez R, López A, Guillén LE, Cesarman G.

Metabolism. 2002 Jan;51(1):44-51.PMID: 11782871 [PubMed - indexed for MEDLINE]Related articles

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.

Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ; GLAI Study Investigators.

Diabetes Care. 2005 Jul;28(7):1547-54.PMID: 15983299 [PubMed - indexed for MEDLINE]Related articlesFree article

Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.

Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA.

J Clin Endocrinol Metab. 2004 Jan;89(1):200-6.PMID: 14715850 [PubMed - indexed for MEDLINE]Related articlesFree article

Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes.

Berneis K, Rizzo M, Stettler C, Chappuis B, Braun M, Diem P, Christ ER.

Expert Opin Pharmacother. 2008 Feb;9(3):343-9.PMID: 18220486 [PubMed - indexed for MEDLINE]Related articles

The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials.

Rajagopalan R, Xu Y, Abbadessa M; Quartet Study Group.

Am J Geriatr Pharmacother. 2006 Jun;4(2):123-33.PMID: 16860259 [PubMed - indexed for MEDLINE]Related articles

Effects of marine n-3 fatty acid supplementation on lipoprotein subclasses measured by nuclear magnetic resonance in subjects with type II diabetes.

Mostad IL, Bjerve KS, Lydersen S, Grill V.

Eur J Clin Nutr. 2008 Mar;62(3):419-29. Epub 2007 Feb 28.PMID: 17327864 [PubMed - indexed for MEDLINE]Related articles

The long-term effects of rosiglitazone on serum lipid concentrations and body weight.

Shim WS, Do MY, Kim SK, Kim HJ, Hur KY, Kang ES, Ahn CW, Lim SK, Lee HC, Cha BS.

Clin Endocrinol (Oxf). 2006 Oct;65(4):453-9.PMID: 16984237 [PubMed - indexed for MEDLINE]Related articles

Thiazolidinediones and blood lipids in type 2 diabetes.

van Wijk JP, de Koning EJ, Martens EP, Rabelink TJ.

Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1744-9. Epub 2003 Aug 7.PMID: 12907465 [PubMed - indexed for MEDLINE]Related articlesFree article

Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.

Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JP.

Diabetes Care. 2004 Jan;27(1):41-6.PMID: 14693964 [PubMed - indexed for MEDLINE]Related articlesFree article

Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes.

Perez A, Khan M, Johnson T, Karunaratne M.

Diab Vasc Dis Res. 2004 May;1(1):44-50.PMID: 16305056 [PubMed - indexed for MEDLINE]Related articles

Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes.

Tan MH, Johns D, Glazer NB.

Clin Chem. 2004 Jul;50(7):1184-8. Epub 2004 Apr 29.PMID: 15117857 [PubMed - indexed for MEDLINE]Related articlesFree article

Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type 1 diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study.

Soedamah-Muthu SS, Chang YF, Otvos J, Evans RW, Orchard TJ; Pittsburgh Epidemiology of Diabetes Complications Study.

Diabetologia. 2003 May;46(5):674-82. Epub 2003 May 13.PMID: 12743701 [PubMed - indexed for MEDLINE]Related articles